Dr Coates discusses her presentation at ACR Convergence on a study that found the risk of developing psoriatic arthritis was lowest among patients with psoriasis who were treated with IL-17 inhibitors compared to those treated with IL-23,...
Dr Coates discusses her presentation at ACR Convergence on a study that found the risk of developing psoriatic arthritis was lowest among patients with psoriasis who were treated with IL-17 inhibitors compared to those treated with IL-23,...
Dr Ramiro reviews her presentation at ACR Convergence on the SPACE cohort study of the difference in structural lesions of the spine as assessed on radiographs and on MRI between patients with early axial SPA and patients with nonaxial SpA...
Dr Ramiro reviews her presentation at ACR Convergence on the SPACE cohort study of the difference in structural lesions of the spine as assessed on radiographs and on MRI between patients with early axial SPA and patients with nonaxial SpA...
Dr Karmacharya reviews his presentation from ACR Convergence a population-based study from the UK THIN database across psoriatic arthritis, psoriasis, and axial spondyloarthritis to find distinct and remarkably stable patterns of...
Dr Karmacharya reviews his presentation from ACR Convergence a population-based study from the UK THIN database across psoriatic arthritis, psoriasis, and axial spondyloarthritis to find distinct and remarkably stable patterns of...
Patients with rheumatic diseases who were not vaccinated against SARS-CoV-2 experienced more severe outcomes throughout the various 'epochs' of the pandemic.
Patients with rheumatic diseases who were not vaccinated against SARS-CoV-2 experienced more severe outcomes throughout the various 'epochs' of the pandemic.
Metabolic dysfunction-associated steatotic liver disease was consistently associated with osteoarthritis across a variety of subgroups, researchers found.
Metabolic dysfunction-associated steatotic liver disease was consistently associated with osteoarthritis across a variety of subgroups, researchers found.
Understand the efficacy and safety of RINVOQ, a once-daily oral JAK inhibitor, for the treatment of active psoriatic arthritis (PsA) in adult TNFi-IR patients.
Understand the efficacy and safety of RINVOQ, a once-daily oral JAK inhibitor, for the treatment of active psoriatic arthritis (PsA) in adult TNFi-IR patients.
